Table 2.

Intravenous glycoprotein IIb/IIIa receptor blockers for patients undergoing percutaneous coronary intervention

			Primary end point
Trial	Patient category	n	IIb/IIIa	Placebo	P value
EPIC [72]	AMI, UA or high-risk lesion	2099	8.3	12.8	0.008
EPILOG [74]	SA	2792	5.2	11.7	< 0.001
CAPTURE [62]	Refractory UA	1265	11.3	15.9	0.01
IMPACT-II [77]	AMI, SA,UA	4010	9.2	11.4	0.06
RESTORE [78]	UA	2139	10.3	12.2	0.16
EPISTENT [103]	AMI, UA, SA and stent eligible	2399	5.3	10.8	< 0.001

See text for details of patient selection, primary end points, and outcome. In the EPIC, EPILOG, CAPTURE and EPISTENT trials, the primary end point consisted of death, acute myocardial infarction (AMI) or target vessel revascularization (TVR) at 30 days. In the IMPACT-II trial, the need for a bailout stent also included a primary end point. In the RESTORE trial, not only TVR was included, but any revascularizations. UA, Unstable angina; SA, stable angina.